CTAD 2024 | Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment

Charbel Moussa, MBBS, PhD, Georgetown University Medical Center, Washington, DC, discusses the potential role of tyrosine kinase inhibitors in the treatment of neurodegenerative diseases and what lessons can be learned from their use in cancer treatment. In the context of neurodegenerative diseases, tyrosine kinase inhibitors could be efficacious by clearing accumulated proteins in the brain or by lowering the level of inflammation. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.